Future Oncology

A tale of three Hs: HPV, HIV & HAART
pp. 1-9(9)
Authors: Stebbing, Justin; Dancey, Gairin; Bower, Mark

Bulletin Board
pp. 11-13(3)

Dexrazoxane use in the prevention of anthracycline extravasation injury
pp. 15-20(6)
Author: Hasinoff, Brian B

Epoetin beta in oncology: examining the current evidence
pp. 21-38(18)
Author: Ludwig, Heinz

Biomathematics in the development of personalized medicine in oncology
pp. 39-42(4)
Author: Agur, Zvia

BRCA2 in mitotic exit: a new role in regulating genomic stability
pp. 43-46(4)
Authors: Wang, Xiaoxing; Dai, Wei

Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC
pp. 47-51(5)
Author: Reck, Martin

The future of photodynamic therapy in oncology
pp. 53-71(19)
Authors: Allison, Ron R; Bagnato, Vanderlei S; Cuenca, Rosa; Downie, Gordon H; Sibata, Claudio H

MicroRNAs as a potential magic bullet in cancer
pp. 73-82(10)
Authors: Slack, Frank J; Weidhaas, Joanne B

FOXO factors: a matter of life and death
pp. 83-89(7)
Authors: Huang, Haojie; Tindall, Donald J

Targeting GSK-3: a promising approach for cancer therapy?
pp. 91-100(10)
Authors: Ougolkov, Andrei V; Billadeau, Daniel D

Targeting the insulin-like growth factor axis as a cancer therapy
pp. 101-110(10)
Authors: Haddad, Tufia; Yee, Douglas

Potential role of pulsed-high intensity focused ultrasound in gene therapy
pp. 111-119(9)
Authors: Frenkel, Victor; Li, King CP

Targeting the ubiquitin–proteasome pathway in breast cancer therapy
pp. 121-135(15)
Authors: Dees, E Claire; Orlowski, Robert Z

Current developments in adenovirus-based cancer gene therapy
pp. 137-143(7)
Authors: Rein, Daniel T; Breidenbach, M; Curiel, David T

Translational regulation of p53 as a potential tumor therapy target
pp. 145-153(9)
Authors: Schumacher, Björn; Gartner, Anton